This World Cancer Day, we spoke to Darshana Ramesh, who was diagnosed with chronic myeloid leukemia in 2021. Her journey - from an unexpected diagnosis in a foreign country to finding the right treatment and understanding her new reality - highlights both the incredible progress in CML care and the challenges that still remain. We spoke to Darshana from her home in Singapore.

2025 is a remarkable milestone in the fight against chronic myeloid leukemia - the 25th anniversary of tyrosine kinase inhibitors (TKIs). The story of TKI development is one of collaboration and courage. A story that formed the basis of the iCMLf, and one that we hope to emulate as we continue working to improve outcomes for people with CML.

Over the coming year we will share highlights of the development, impact and future opportunities of this incredible therapy. To begin, we share a message from Professor Jorge Cortes and Professor Brian Druker.

January 2025 - There is still time to recognise outstanding contributions to CML research and patient management with one of the three 2025 iCMLf Prizes:

🥇 The Rowley Prize – For groundbreaking contributions to CML biology.
🥇 The Goldman Prize – Recognising transformative advancements in CML patient care.
🥇 The iCMLf Prize – Highlighting exceptional efforts to overcome CML treatment challenges in low- and middle-income countries.

Submit your nominations by January 31^st

January 2025 - This is a friendly reminder to join us for the CML Highlights of ASH 2024 webinar, the first iCMLf Conversation of 2025, taking place on:

📅Thursday, January 23rd, 2025
🕐 13:00 Central European Time (CET)
📍 Live webinar on Zoom (45 mins)

Click here for more information and times in other time zones.

Zoom Access: Click here to join
Meeting ID: 828 8939 5232

January 2025 - The risk of Hepatitis B Virus (HBV) reactivation in CML patients under TKI therapy has been reported, but there are no clear guidelines and recommendations regarding screening and monitoring of HBV in CML patients receiving TKIs and experience on Hepatitis B reactivation under CML treatment is limited.

On the initiative of Professor Dragana Milojkovic (Imperial College London, UK), the iCMLf has formed a HBV and CML Working Group to answer open research questions. This group will collect and collate global experiences of physicians treating people with CML and HBV, with the aim of developing recommendations on monitoring and treatment for HBV in patients with CML.

The iCMLf Hepatitis B virus (HBV) Screening and Management Survey is now open and we would be delighted to learn from you.

December 2024 - We are delighted to invite you to our ‘CML Highlights of ASH 2024’ webinar, the first iCMLf Conversation of 2025, where we will present key insights and updates from the 66th American Society of Hematology (ASH) Meeting 2024.

If you missed the ASH 2024 Meeting or want an expert overview, this webinar offers a concise and comprehensive summary of the key CML clinical and biological highlights from the conference.

Join us on Thursday, January 23^rd, 2025 at 13.00 CET to hear from two world-renowned experts:

Professor Timothy Hughes:
Sharing clinical advancements in CML presented at ASH 2024
Professor Susan Branford:
Highlighting biological breakthroughs in CML presented at ASH 2024

Page 2 of 46

Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK